S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research.
CONCLUSIONS: S-adenosylmethionine holds promise as a treatment for multiple neuropsychiatric conditions, but the body of evidence has limitations. The encouraging findings support further study of SAMe in both psychiatric and comorbid medical illnesses.
PMID: 28682528 [PubMed - in process]
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
More News: Alzheimer's | Anxiety | Brain | Cirrhosis | Clinical Trials | Databases & Libraries | Dementia | Depression | Fibromyalgia | Hepatitis | Microdeletion Syndromes | Neurology | Osteoarthritis | Parkinson's Disease | Perinatology & Neonatology | Psychiatry | Schizophrenia | Study | Substance Abuse | Substance Abuse Disorders